Thulliez M, et al. - Systemic adverse events related to intravitreal anti–vascular endothelial growth factor (anti-VEGF) treatments in patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion were determined analyzing data from meta-analyses and systematic reviews. No increased risk of systemic adverse events was noted in association with anti-VEGF treatments. Caution might be advisable in older patients with age-related macular degeneration who may be at higher risk of hemorrhagic events when receiving ranibizumab.